Stock Track | Pharvaris N.V. Soars 5.94% on Analyst Optimism

Stock Track

Nov 22, 2024

Shares of Pharvaris N.V. (PHVS) surged 5.94% on Friday, marking a strong finish to the trading week for the biopharmaceutical company. The stock's intraday surge came amid bullish analyst sentiment.

Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Pharvaris and set a price target of $34.00, reflecting a significant upside potential from current levels. The analyst's positive outlook appears to be fueling investor optimism and driving the stock higher.

Pharvaris is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare diseases. The company's promising pipeline and growth prospects have caught the attention of Wall Street analysts, contributing to the stock's recent momentum.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1192239733"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1192239733\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1192239733?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-22 23:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192239733","market":"hk","top_or_hot":-1,"title":"Stock Track | Pharvaris N.V. Soars 5.94% on Analyst Optimism","media":"Stock Track","content":"<p>Shares of Pharvaris N.V. (PHVS) surged 5.94% on Friday, marking a strong finish to the trading week for the biopharmaceutical company. The stock's intraday surge came amid bullish analyst sentiment.</p>\n\n<p>Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Pharvaris and set a price target of $34.00, reflecting a significant upside potential from current levels. The analyst's positive outlook appears to be fueling investor optimism and driving the stock higher.</p>\n\n<p>Pharvaris is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare diseases. The company's promising pipeline and growth prospects have caught the attention of Wall Street analysts, contributing to the stock's recent momentum.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Pharvaris N.V. Soars 5.94% on Analyst Optimism</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Pharvaris N.V. Soars 5.94% on Analyst Optimism\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-22 23:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Pharvaris N.V. (PHVS) surged 5.94% on Friday, marking a strong finish to the trading week for the biopharmaceutical company. The stock's intraday surge came amid bullish analyst sentiment.</p>\n\n<p>Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Pharvaris and set a price target of $34.00, reflecting a significant upside potential from current levels. The analyst's positive outlook appears to be fueling investor optimism and driving the stock higher.</p>\n\n<p>Pharvaris is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare diseases. The company's promising pipeline and growth prospects have caught the attention of Wall Street analysts, contributing to the stock's recent momentum.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PHVS","symbol_name":"Pharvaris N.V.","start_time":0,"source_url":"","article_id":"1192239733","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192239733","pubTimestamp":1732290256,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Pharvaris N.V.  surged 5.94% on Friday, marking a strong finish to the trading week for the biopharmaceutical company. The stock's intraday surge came amid bullish analyst sentiment.Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Pharvaris and set a price target of $34.00, reflecting a significant upside potential from current levels. The analyst's positive outlook appears to be fueling investor optimism and driving the stock higher.Pharvaris is a clinical-stage biopharm","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PHVS":"Pharvaris N.V."},"translate_title":"分析师乐观情绪推动Pharvaris N.V.股价飙升5.94%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHVS":1},"content_text":"Shares of Pharvaris N.V. (PHVS) surged 5.94% on Friday, marking a strong finish to the trading week for the biopharmaceutical company. The stock's intraday surge came amid bullish analyst sentiment.\nMorgan Stanley analyst Maxwell Skor maintained a Buy rating on Pharvaris and set a price target of $34.00, reflecting a significant upside potential from current levels. The analyst's positive outlook appears to be fueling investor optimism and driving the stock higher.\nPharvaris is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare diseases. The company's promising pipeline and growth prospects have caught the attention of Wall Street analysts, contributing to the stock's recent momentum.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}